Mr. Allen Davidoff reports

XORTX ANNOUNCES CHANGE OF EFFECTIVE DATE OF SHARE CONSOLIDATION

XORTX Therapeutics Inc., further to its news release of March 25, 2026, has delayed the implementation of its share consolidation on the basis of one new common share for every five old common shares from March 27, 2026, to April 6, 2026. The rollback remains subject to the receipt of all required approvals of the TSX Venture Exchange and Nasdaq Stock Exchange.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: (1) its lead program XRx-026 program for the treatment of gout; (2) XRx-008 program for ADPKD; and (3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the company is developing XRx-225, a preclinical-stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. XORTX is dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases.

We seek Safe Harbor.